SPARC Share Price: Revenue **43%** Gira, Loss Badha, Company 'Going Concern' Alert par? PRV Voucher Awarded!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
SPARC Share Price: Revenue **43%** Gira, Loss Badha, Company 'Going Concern' Alert par? PRV Voucher Awarded!
Overview

Suno suno! SPARC ke Q3 Results ekdum gir gaye hain. Company ka revenue **43.39%** down ho gaya hai aur loss bhi kaafi zyada hai. Aur tension wali baat yeh hai ki company ne khud kaha hai woh 'Going Concern' alert par hai, matlab financial situation stable nahi hai aur promoters ke support par nirbhar hai.

📉 SPARC ke Numbers ka Kya Scene Hai?

Sun Pharma Advanced Research Company (SPARC) ne apni Q3 FY26 ki results release ki hain aur bhai, numbers kaafi disappointing hain. Company ka revenue 43.39% seedha neeche gira hai, jo ki ₹845 Lakhs tak aa gaya hai, last year isi quarter mein yeh ₹1,491 Lakhs tha. Agar poore 9 mahine ki baat karein, toh revenue 42.03% kam hokar ₹2,595 Lakhs ho gaya hai.

Is revenue drop ka effect loss par bhi dikh raha hai. Consolidated basis par, Q3 mein company ko ₹7,923 Lakhs ka net loss hua hai, jo last year ke ₹7,941 Lakhs se thoda kam hai. Lekin 9 mahine ka consolidated loss abhi bhi ₹20,692 Lakhs hai, haan, yeh pehle se kam zaroor hua hai.

Standalone basis par bhi situation alag nahi hai. Quarter ke liye net loss before tax ₹8,057 Lakhs tha, jisse diluted EPS ₹(2.48) raha. 9 mahino ka standalone net loss before tax ₹20,857 Lakhs raha aur diluted EPS ₹(6.43) raha.

Aur ek extra stress point yeh hai ki company ne is quarter mein ₹1,236 Lakhs ka exceptional item record kiya hai, jo ki India ke naye labour codes ko implement karne ki wajah se hua hai. Isse cost pressure aur badh gaya.

🚩 Sabse Badi Chinta: 'Going Concern' Alert

Ab sabse alarming baat, company ne khud kaha hai ki woh 'Going Concern' hai. Iska matlab hai ki company apne pichle losses aur current cash losses ki wajah se future mein business chalati rahegi ya nahi, yeh uncertain hai. Company ka operational continuity completely promoter group ke support letter pe depend kar raha hai. Matlab, company khud se cash generate nahi kar pa rahi hai aur bahari support ki zaroorat pad rahi hai. Yeh investors ke liye badi red flag hai.

✨ Ek Achhi Khabar: Sezaby® PRV Voucher

Par haan, ek achi khabar bhi hai! US FDA ne Sezaby® ke liye ek Rare Pediatric Disease Priority Review Voucher (PRV) award kiya hai. Yeh vaccine ke approval ke saath mila hai aur yeh voucher future mein bik sakta hai, jisse company ko revenue mil sakta hai. Is voucher ki value achhi ho sakti hai, par abhi iska exact financial impact clear nahi hai.

SPARC ka poora business Pharmaceutical Research and Development pe tuka hua hai. Current results dikhate hain ki R&D mein challenges chal rahe hain, jabki PRV voucher ek potential asset hai. Investors ab dekhenge ki company promoter support aur PRV voucher ke saath future mein kaise perform karti hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.